The munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 6 constituents from our Pure-Play Marijuana Drug Stocks Index sub-category and 12 from our Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which index performed the best in 2021? Which constituents contributed to their performances? How do they compare? This article has the answers.

One hundred (100) clinical-stage psychedelic drug stocks now trade on North American stock exchanges. Sixty (60) of them (see here) research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them) and 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know). The criteria for inclusion in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $35M (only eight have market caps below $100M) and only 18 of those 100 psychedelic drug stocks meet that criteria.

Pure-Play Marijuana Drug Stocks Index

The constituents in both our Pure-Play Marijuana Drug Stocks Index and our Pure-Play Psychedelic Compounds-Based Drug Stocks Index have hyperlinks to 3 areas of additional information which are imperative for any individual considering investing in this sector:

• The company name is hyperlinked to its website to provide you with a description of the company and an analysis of its stock.
• The trading symbol is hyperlinked to additional financial data and commentary on the company (where available).
• The percentage increase YTD is hyperlinked to a chart of the company's stock performance YTD.

The "financial distress" percentage is sourced from macroaxis.com (visit the site and type in the stock symbol to obtain detailed financial data on the health of the company).

The 6 marijuana-based clinical-stage stocks went DOWN -35.7% in 2021. The performance of the constituents in 2021 are presented below in descending order:

1. Allied Corp. (ALID): UP +136.0%
   • engaged in the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder
   • has about a 24% chance of experiencing some form of financial distress in the next two years of operation
2. Zynerba (ZYNE): DOWN -12.9%
   • operates as a clinical stage specialty pharmaceutical company
   • has more than a 55% chance of experiencing financial distress in the next 2 years of operation
3. Tetra Bio (TBPMF): DOWN -40.0%
   • engages in the discovery and development of immunomodulator drugs including PPP003 for painful dry eye and uveitis pain and HCC011 for hepatocellular carcinoma
   • has about a 28% chance of experiencing financial distress in the next 2 years of operation
4. Revive (RVVTF): DOWN -44.9%
   • focuses on the research and development of therapeutics for rare disorders and infectious diseases
   • has a very small chance of experiencing financial distress in the next few years
5. Corbus (CRBP): DOWN -50.4%
   • focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer
   • has a greater than 89% chance of experiencing financial distress in the next few years of operation
6. Enveric (ENVB): DOWN -78.2%; yes, -78.2%
   • developing cannabinoid medicines for cancer care such as radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy
   • has over a 58% chance of experiencing financial distress in the next 2 years of operation

The munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index

The 12 psychedelic compound-based clinical-stage stocks are divided into 2 groups based on their market capitalizations.

The 9 constituents with market caps below $1B were DOWN -32.4% in 2021 and their performances are presented below in descending order:

1. Seelos (SEEL): UP +3.2%
   • focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
   • has over a 74% chance of experiencing financial distress in the next few years of operation.
2. Awakn (AWKNF): DOWN -6.0% since launch on June 23rd
   • engaged in researching and developing psychedelic drugs focuses to treat addiction as well as delivering psychedelic treatments for addiction in clinics in the UK and EU.
   • has a 50% chance of experiencing financial distress in the next 2 years of operation.
   • Read: Awakn Life Sciences: Wake Up To The Huge Potential
3. Cybin (CYBN): DOWN -20.0%
   • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
   • has over a 62% chance of experiencing financial distress in the next few years of operation.
4. Field Trip (FTRP): DOWN -24.3%
   • focused on building centers for psychedelic therapies across North America and Europe.
   • has about a 27% chance of experiencing some form of financial distress in the next two years of operation.
5. Small Pharma (DMTTF): DOWN -30.6% since launch in June, 2021
   • focused on developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders.
   • has over a 77% chance of experiencing some form of financial distress in the next two years of operation
6. Mind Medicine (MNMD): DOWN -54.8%
   • focused on the development of a pipeline of treatments to address addiction and mental illness based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
   • has over a 58% chance of experiencing financial distress in the next few years of operation.
7. Numinus (NUMIF): DOWN -50.0%
   • provides clients with testing of controlled compounds such as LSD, ketamine, DMT, MDMA, mescaline, psilocybin and psilocin as well as conducting research of both MDMA and psilocybin to treat PTSD, depression, anxiety, and addiction.
   • has over a 77% chance of experiencing financial distress in the next few years of operation
8. Red Light (TRUFF) DOWN -56.0%
   • plans to produce, market, and distribute a premium health and wellness brand of psilocybin truffles within the Netherlands.
   • has less about a 25% chance of experiencing financial distress in the next few years of operation.
9. Mydecine (MYCOF): DOWN -68.6%; yes, -68.6%!
   • focused on clinical trials focusing on veterans, EMS, and first responders with a PTSD indication.
   • has about a 24% chance of experiencing some form of financial distress in the next two years of operation.

The 3 constituents with market caps above $1B were DOWN -16.5% in 2021 and their performances are presented below in descending order:

1. GH Resources (GHRS): UP +21.2%
2. Compass Pathways (CMPS): DOWN -53.6%
3. Atai (ATAI): DOWN -57.7%

On average, the 12 constituents in the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index went DOWN -33.6% in 2021 and now have an average market capitalization of $410M.

In Summary

In answer to the opening question as to which Index did the best in 2021:

• the munKNEE Pure-Play Marijuana Drug Stocks Index went DOWN -35.7% in 2021
• the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index went DOWN -32.4% in 2021
• the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index of all 18 constituents went DOWN -33.6% in 2021.